Cat. No. | Name/Description | Purity |
---|---|---|
A697812 | Palmatine chloride | 98% |
A600112 | GSK-1070916 | 99% |
A405855 | SNS-314 mesylate | 98% |
A363646 | Barasertib | 98% |
A917251 | CCT 137690 | 98% |
A108356 | MK-5108 | 98% |
A107524 | ZM-447439 | 98% |
A302242 | TAK-901 | 98% |
A306611 | KW-2449 | 99% |
A102516 | Alisertib | 98% |
A153304 | Barasertib-HQPA | 98% |
A1177300 | CCT241736 | 98% |
A531108 | MLN8054 | 98+% |
A146183 | (Z)-Orantinib | 97% |
A1142860 | Aurora kinase inhibitor-3 | 98% |
A1461903 | Chiauranib | 97% |
A1195004 | BPR1K871 | 98% |
A165443 | PHA-680632 | 98% |
A1176612 | NU6140 | 99% |
A262123 | JNJ-7706621 | 98% |
Name/Description | Aurora A ↓ ↑ | Aurora B ↓ ↑ | Aurora C ↓ ↑ | Other Targets | Purity | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MK-5108 |
++++
Aurora A, IC50: 0.064 nM |
99%+ | |||||||||||||||||
KW-2449 |
+
Aurora A, IC50: 48 nM |
FLT3 | 99%+ | ||||||||||||||||
AT9283 |
++++
Aurora A, IC50: ~3.0 nM |
++++
Aurora B, IC50: ~3.0 nM |
99%+ | ||||||||||||||||
MLN8054 |
+++
Aurora A, IC50: 4 nM |
+
Aurora B, IC50: 172 nM |
99%+ | ||||||||||||||||
ZM-447439 |
+
Aurora A, IC50: 110 nM |
+
Aurora B, IC50: 130 nM |
Src | 99%+ | |||||||||||||||
TCS7010 |
++++
Aurora A, IC50: 3.4 nM |
99%+ | |||||||||||||||||
TAK-901 |
++
Aurora A-TPX2, IC50: 21 nM |
++
Aurora B-INCENP, IC50: 15 nM |
99%+ | ||||||||||||||||
MK-8745 |
++++
Aurora A, IC50: 0.6 nM |
99+% | |||||||||||||||||
Alisertib |
++++
Aurora A, IC50: 1.2 nM |
99%+ | |||||||||||||||||
ENMD-2076 |
+++
Aurora A, IC50: 14 nM |
+
Aurora B, IC50: 350 nM |
FLT3 | 99% | |||||||||||||||
JNJ-7706621 |
+++
Aurora A, IC50: 11 nM |
++
Aurora B, IC50: 15 nM |
99%+ | ||||||||||||||||
CYC-116 |
+++
Aurora A, Ki: 8 nM |
+++
Aurora B, Ki: 9 nM |
FLT3 | 99%+ | |||||||||||||||
Barasertib-HQPA |
++++
Aurora B, IC50: 0.37 nM |
99%+ | |||||||||||||||||
Hesperadin |
+
Aurora B (human), IC50: 250 nM |
99%+ | |||||||||||||||||
BI-847325 |
++
Aurora A (Human), IC50: 25 nM |
++++
Aurora B (Xenopus laevis), IC50: 3 nM |
++
Aurora C (Human), IC50: 15 nM |
99%+ | |||||||||||||||
CCT 137690 |
++
Aurora A, IC50: 15 nM |
++
Aurora B, IC50: 25 nM |
++
Aurora C, IC50: 19 nM |
99%+ | |||||||||||||||
Tozasertib |
++++
Aurora A, Ki app: 0.6 nM |
++
Aurora B, Ki app: 18 nM |
+++
Aurora C, Ki app: 4.6 nM |
Bcr-Abl,FLT3 | 99%+ | ||||||||||||||
GSK-1070916 |
++++
Aurora B-INCENP, IC50: 3.5 nM |
+++
Aurora C-INCENP, IC50: 6.5 nM |
Tie-2,SIK | 99% | |||||||||||||||
Danusertib |
+++
Aurora A, IC50: 13 nM |
+
Aurora B, IC50: 79 nM |
+
Aurora C, IC50: 61 nM |
99%+ | |||||||||||||||
PHA-680632 |
++
Aurora A, IC50: 27 nM |
+
Aurora B, IC50: 135 nM |
+
Aurora C, IC50: 120 nM |
FLT3 | 99%+ | ||||||||||||||
AMG 900 |
+++
Aurora A, IC50: 5 nM |
+++
Aurora B, IC50: 4 nM |
++++
Aurora C, IC50: 1 nM |
99%+ | |||||||||||||||
Reversine |
+++
Aurora A, IC50: 12 nM |
+++
Aurora B, IC50: 13 nM |
++
Aurora C, IC50: 20 nM |
98% | |||||||||||||||
CCT129202 |
++
Aurora A, IC50: 42 nM |
+
Aurora B, IC50: 198 nM |
+
Aurora C, IC50: 227 nM |
98% | |||||||||||||||
SNS-314 mesylate |
+++
Aurora A, IC50: 9 nM |
++
Aurora B, IC50: 31 nM |
++++
Aurora C, IC50: 3 nM |
99%+ | |||||||||||||||
1. Hovering the mouse over the "+" can display the specific value of the relevant IC50. The more "+", the stronger the inhibitory effect. 2. "✔" Indicates that the compound has inhibitory effects on the corresponding subtypes, but there is currently no relevant data on the intensity of inhibition. |